SHR-1701 injection

DRUG2 trials

Sponsors

Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd.

Conditions

Advanced Gastric CancerGastroesophageal Junction AdenocarcinomaMetastatic Gastric CancerPerioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

Phase 2

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

TerminatedNCT05149807

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

Start: 2022-01-26End: 2024-04-03Updated: 2025-08-20

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

RecruitingNCT07102901

Jiangsu HengRui Medicine Co., Ltd.Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Cancer

Start: 2025-09-05End: 2027-12-31Target: 351Updated: 2025-09-10